 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...234567891011121314 |
- | psilocybin / Compass Pathways
Journal: Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. (Pubmed Central) - Apr 28, 2019
These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.
- | psilocybin / Compass Pathways
Journal: Psychedelics as a treatment for disorders of consciousness. (Pubmed Central) - Apr 27, 2019
Based on its ability to increase brain complexity, a seemingly reliable index of conscious level, we propose testing the capacity of the classic psychedelic, psilocybin, to increase conscious awareness in patients with disorders of consciousness. We also confront the considerable ethical and practical challenges this proposal must address, if this hypothesis is to be directly assessed.
- ||| psilocybin / Compass Pathways
Spent the weekend in the lab hosting Anderson Cooper and the 60 Minutes crew, who were checking out #psilocybin research. #psychedelics (Twitter) - Apr 15, 2019
- | psilocybin / Compass Pathways
#LegalizeMarijuana #LegalizeCannabis #EndTheDrugWar #LegalizeIt #LegalizeAmerica #LegalizePsilocybin #LegalizeNature (Twitter) - Apr 11, 2019
- || psilocybin / Compass Pathways
Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. https://t.co/boaCMrrUzc (Twitter) - Apr 10, 2019
- | psilocybin / Compass Pathways
Journal: Enzymatic synthesis of psilocybin. (Pubmed Central) - Apr 5, 2019
In a combined PsiD/PsiK/PsiM reaction, psilocybin was synthesized enzymatically in a step-economic route from 4-hydroxy-l-tryptophan. Given the renewed pharmaceutical interest in psilocybin, our results may lay the foundation for its biotechnological production.
- | psilocybin / Compass Pathways
Journal: Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. (Pubmed Central) - Mar 30, 2019
...In previous studies, similarities were observed between psilocybin, LSD, and ayahuasca, with respect to decreases in cerebral blood flow and increases in global functional connectivity in the precuneus and thalamus...Little convergence was observed for connectivity between networks and for blood flow in other brain regions. Although these studies are limited by small sample sizes and might be biased by unspecific drug effects on physiological parameters and the vascular system, current results indicate that neuroimaging could be a useful tool to elucidate the neuronal correlates of hallucinogenic effects.
- | psilocybin / Compass Pathways
Journal: d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. (Pubmed Central) - Mar 30, 2019
Randomized clinical studies have confirmed its antidepressant and anxiolytic effects in humans. Thus, in this chapter, we will review the pharmacology of psychedelic drugs, report the most striking clinical evidence which substantiate the therapeutic potentials of these fascinating compounds in mood disorders, and look into the horizon of where psychedelic medicine is heading.
- | psilocybin / Compass Pathways
Journal: Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition. (Pubmed Central) - Mar 30, 2019
In addition, we find enhanced signatures of criticality suggesting that the brain dynamics tune toward criticality in both psychedelic elicited states. Overall, our findings provide new evidence for the remarkable ability of psychedelics to change the spatiotemporal dynamics of the human brain.
- || psilocybin / Compass Pathways
@Drug_Researcher I have a few questions about your research. What are the potential effects of psilocybin, and what are the medical uses of this drug? Does LSD apply to the list of medicinal psychedelics? What are the potential economic effects of regulation of psychedelics? Thx. (Twitter) - Mar 27, 2019
- | psilocybin / Compass Pathways
Journal: Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. (Pubmed Central) - Mar 25, 2019
Psilocybin decreases the connectivity between important nodes linked to emotion processing like the frontal pole or the striatum. Future studies are needed to clarify whether connectivity changes predict therapeutic effects in psychiatric patients.
- | psilocybin / Compass Pathways
Journal: Modeling Retention Behavior on Analysis of Hallucinogenic Mushrooms Using Hydrophilic Interaction Liquid Chromatography. (Pubmed Central) - Mar 23, 2019
...An extract of a truffle-like fungus containing psilocin, psilocybin and baeocystin was chosen as test material...It was found the best modeling was obtained by using the quadratic approach to predict chromatograms for predefined chromatographic conditions (volumetric ratio of acetonitrile to buffer, pH of the buffer and temperature), while the exponential model proved to be the worst for prediction. The modeling with multivariate data analysis fell between the other two methods.
- | psilocybin (COMP360) / Compass Pathways
New P2 trial: The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (clinicaltrials.gov) - Dec 13, 2018
P2, N=216, Recruiting, Sponsor: COMPASS Pathways